What is the 13F Pro Quality Score for VTRS?

13F Pro ranks Viatris Inc (VTRS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTRS's current score at https://13fpro.ai/company/VTRS (free sign-up required for the full ranking).

Which hedge funds own the most VTRS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VTRS include FMR, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/VTRS as soon as new 13F filings post.

Where does 13F Pro source VTRS data?

All Viatris Inc fundamentals and ownership data come directly from SEC EDGAR. Viatris Inc files with the SEC under CIK 1792044. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTRS in?

Viatris Inc (VTRS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTRS research updated on 13F Pro?

VTRS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Viatris Inc(VTRS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1792044 VTRS stock profile & AI dashboard →

13F Pro Quality Score

45.4/100

Rank #1,869 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

19.0/100

Profitability

30.0/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

62.3/100

Institutional Flow

85.2/100

Revenue Scale

89.9/100

Dilution Risk

51.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VTRS Scores 45/100

exact factor attribution · 2026-09-11

VTRS's composite is driven by scale and free cash flow, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.0 pts

90th pct

Free cash flow

+1.8 pts

62th pct

Institutional flow

+1.8 pts

85th pct

Shareholder dilution

+0.1 pts

51th pct

Earnings growth

-1.0 pts

30th pct

Capital efficiency

-2.0 pts

30th pct

Earnings quality

-2.0 pts

30th pct

Profitability

-3.0 pts

30th pct

Revenue growth

-6.2 pts

19th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VTRS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Viatris Inc (VTRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VTRS at 45.4/100 on a 32-signal composite quality model, placing it at rank #1,869 of 2,961 stocks — the bottom half of the AI-ranked universe. VTRS scores in the top quartile across revenue scale (89.9), institutional flow (85.2). Areas of concern include revenue growth (19.0) and profitability (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Viatris Inc reports quarterly revenue of $3.8B, net income of $-118.8M, an operating margin of 0.2%. Top institutional holders of VTRS by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VTRS trades on the Nasdaq exchange and files with the SEC under CIK 1792044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viatris Inc directly from SEC EDGAR. Viatris Inc's 13F Pro composite quality score has ranged between 34 and 63 since 2021, currently 45.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Viatris Inc

Quirks, history, and lore behind VTRS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · large-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of $15–17 billion, yet it has carried a heavy debt load since its creation — servicing that pile is basically a part-time job.
3
The History
Born in 2020 from a mega-merger of two pharma giants — one American, one Irish — creating one of the world's largest off-patent drug makers almost overnight.
4
The Secret
Its business model leans hard on generic and off-patent medicines, meaning it competes mostly on price and scale rather than blockbuster R&D breakthroughs.
5
The Lore
It inherited a massive portfolio including the EpiPen — one of the most controversial drug-pricing stories in recent U.S. history — along with brands like Lipitor and Viagra in their generic forms.
6
The Giveaway
The offspring of Mylan and Pfizer's Upjohn division, this company's very name is a mashup of "via" and "matrix" — your last hint before the ticker reveals all.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$3.8B

Net Income

Q2 2026

$-118.8M

Free Cash Flow

Q2 2026

$329.0M

Operating Margin

Q2 2026

0.2%

ROIC

Q2 2026

0.1%

D/E Ratio

Q2 2026

1.06

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-3.0% YoY

$14.30BFY 2025

FY22 $16.26BFY23 $15.43BFY24 $14.74BFY25 $14.30B

Operating Income

-26467.3% YoY

$-2.66BFY 2025

FY22 $1.61BFY23 $766.2MFY24 $10.1MFY25 $-2.66B

EPS (Diluted)

-466.0% YoY

$-3.00FY 2025

FY22 $1.71FY23 $0.05FY24 $-0.53FY25 $-3.00

Total Assets

-10.4% YoY

$37.19BFY 2025

FY22 $50.02BFY23 $47.69BFY24 $41.50BFY25 $37.19B

Total Debt

+16.3% YoY

$16.34BFY 2025

FY22 $20.52BFY23 $20.07BFY24 $14.05BFY25 $16.34B

Op. Cash Flow

+0.6% YoY

$2.32BFY 2025

FY22 $3.00BFY23 $2.90BFY24 $2.30BFY25 $2.32B

Free Cash Flow

-2.0% YoY

$1.94BFY 2025

FY22 $2.59BFY23 $2.52BFY24 $1.98BFY25 $1.94B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$14.30B -3.0%	$14.74B -4.5%	$15.43B -5.1%	$16.26B -9.1%	$17.89B +49.7%	$11.95B
Operating Income	$-2.66B -26467.3%	$10.1M -98.7%	$766.2M -52.6%	$1.61B +4849.7%	$-34.0M +83.9%	$-210.8M
EPS (Diluted)	$-3.00 -466.0%	$-0.53 -1160.0%	$0.05 -97.1%	$1.71 +262.9%	$-1.05 +5.4%	$-1.11
Total Assets	$37.19B -10.4%	$41.50B -13.0%	$47.69B -4.7%	$50.02B -8.8%	$54.84B -10.9%	$61.55B
Total Debt	$16.34B +16.3%	$14.05B -30.0%	$20.07B -2.2%	$20.52B -17.7%	$24.95B -11.2%	$28.09B
Operating Cash Flow	$2.32B +0.6%	$2.30B -20.6%	$2.90B -3.3%	$3.00B -0.6%	$3.02B +144.9%	$1.23B
Free Cash Flow	$1.94B -2.0%	$1.98B -21.6%	$2.52B -2.7%	$2.59B +1.3%	$2.56B +158.9%	$988.8M

Get alerted when VTRS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Viatris Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTRS

FMR LLC
$1.5B96,662,102 sh
BlackRock, Inc.
$1.4B86,019,468 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B76,046,939 sh
DAVIS SELECTED ADVISERS
$1.2B75,232,254 sh
PRICE T ROWE ASSOCIATES INC /MD/
$1.1B68,214,436 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$862.0M54,282,080 sh
STATE STREET CORP
$842.7M53,069,461 sh
Rubric Capital Management LP
$542.6M34,168,743 sh
GEODE CAPITAL MANAGEMENT, LLC
$520.1M32,807,906 sh
DIMENSIONAL FUND ADVISORS LP
$476.0M29,970,094 sh

Fund	Value	Shares
FMR LLC	$1.5B	96,662,102
BlackRock, Inc.	$1.4B	86,019,468
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	76,046,939
DAVIS SELECTED ADVISERS	$1.2B	75,232,254
PRICE T ROWE ASSOCIATES INC /MD/	$1.1B	68,214,436
VANGUARD PORTFOLIO MANAGEMENT LLC	$862.0M	54,282,080
STATE STREET CORP	$842.7M	53,069,461
Rubric Capital Management LP	$542.6M	34,168,743
GEODE CAPITAL MANAGEMENT, LLC	$520.1M	32,807,906
DIMENSIONAL FUND ADVISORS LP	$476.0M	29,970,094

Companies Similar to VTRS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

OGN

Organon & Co.

AI score

Very similar · 10 shared holders

LSV ASSET MANAGEMENT NEW YORK LIFE INVESTMENT MANAGEMENT LLC CM Management, LLC

PFE

PFIZER INC

AI score

Very similar · 16 shared holders

LSV ASSET MANAGEMENT DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Brandywine Global Investment Management, LLC

GEHC

GE HealthCare Technologies Inc.

AI score

Very similar · 20 shared holders

LSV ASSET MANAGEMENT WEDGE CAPITAL MANAGEMENT L L P/NC Invenomic Capital Management LP

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Very similar · 20 shared holders

THOMPSON SIEGEL & WALMSLEY LLC MOORE CAPITAL MANAGEMENT, LP LSV ASSET MANAGEMENT

BDX

BECTON DICKINSON & CO

AI score

Very similar · 13 shared holders

Invenomic Capital Management LP LEVIN CAPITAL STRATEGIES, L.P.STOREBRAND ASSET MANAGEMENT AS

CVS

CVS HEALTH Corp

AI score

Very similar · 21 shared holders

DAVIS SELECTED ADVISERS GLENVIEW CAPITAL MANAGEMENT, LLC LSV ASSET MANAGEMENT

GILD

GILEAD SCIENCES, INC.

AI score

Very similar · 19 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC Robeco Institutional Asset Management B.V.

MRK

Merck & Co., Inc.

AI score

Very similar · 12 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC Robeco Institutional Asset Management B.V.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTRS on your watchlist

Track score changes the day Viatris Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTRS a good stock to buy?

13F Pro's AI-powered analysis of Viatris Inc (VTRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTRS are available on the VTRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VTRS is classified as a large company.

Which hedge funds own VTRS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viatris Inc's investment landscape.